AzTrials
AzTrials

Severe Mental IllnessPhase 2NCT05432089

The Effects of Oxytocin Administration to Patients and Therapists on Physiological Synchronization

A Phase 2 study testing Intranasal Oxytocin in people with Severe Mental Illness, run by Shalvata Mental Health Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Introduction: Oxytocin (OT) is a nine-amino acid neuropeptide, known to have a fundamental role in social communication. In a recent randomized, double-blind, placebo-controlled study carried out in Shalvata Mental Health Center, OT was administrated to patients suffering from severe mental health illness. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Severe Mental Illness
What is being tested?
Intranasal Oxytocin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 siteIsrael
Study dates
30 Mar 2023to 1 Jul 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Patients Inclusion Criteria:

  • age above 18.
  • any type of psychiatric illness.
  • hospitalization in one of the inpatients wards.

Patients Exclusion Criteria:

  • current severe psychotic episode
  • pregnancy according to self-report.

Therapist Inclusion Criteria:

  • psychologists, psychiatrists, and social workers, in different stages of seniority and training.

Therapist Exclusion Criteria:

  • pregnancy according to self-report.

Trial locations and contacts

1 site in 1 country.

Omer Sedoff, MA contact

+97297478555

omerse@clalit.org.il

Israel1 site, 1 recruiting
  • Shalvata Mental health Center

    Hod HaSharon

    Dana Tzur Bitan, Prof.

    Recruiting

Other trials in Israel

About this study

Official title: The Effects of Oxytocin Administration to Patients and Therapists on Physiological Synchronization: a Randomized Controlled Pilot Study

Introduction: Oxytocin (OT) is a nine-amino acid neuropeptide, known to have a fundamental role in social communication. In a recent randomized, double-blind, placebo-controlled study carried out in Shalvata Mental Health Center, OT was administrated to patients suffering from severe mental health illness. The results indicated that OT has a clear beneficial effect on therapeutic outcomes. However, to our knowledge, the effect of OT administration to both patients and therapists on the therapeutic process was never tested. Substance administration to caregivers is therefore possible, and could, in some cases, provide further knowledge about the caregiving dynamics. Since we know the therapist's characteristics effect the therapeutic alliance and that OT is associated with the therapeutic alliance, patient-therapist bond, and therapy outcome, we are led to ask if OT administration to patients and therapists could allow for a deeper understanding of OT's effects on the therapeutic process.

Another variable found to be associated with the therapeutic process is Physiological Synchronization. Physiological Synchronization (PS) is a primarily interpersonal phenomenon which includes coordination of physiological signals between two or more interacting individuals. Despite the rising number of studies examining PS, its physiological and psychological mechanisms are yet to be fully understood. Based on literature indicating associations between OT and PS, and associations each of them has with the therapeutic process and its facilitators, in this study we wish to examine the influence of OT on PS through intranasal OT administration to patients alone and to patients and therapists together.

Read more

Research Hypotheses:

  1. Patients receiving OT will demonstrate higher levels of PS during the measured session compared to patients receiving placebo.
  2. Patients receiving OT will report higher levels of perceived therapist empathy as compared to patients receiving placebo.
  3. These associations will be stronger when both patient and therapist receive OT in comparison to patient alone.
  4. Changed in PS and empathy will be associated with OT even after controlling for patient rated alliance and session impact.
  5. These findings will sustain after controlling for severity of symptoms and attachment patterns.

Method:

Participants. Sixty patients and their therapists will be recruited for the pilot study. Patients will be recruited from the inpatient adult psychiatric wards at Shalvata Mental Health Center. Therapists in this study will be comprised of psychologists, psychiatrists, and social workers, in different stages of seniority and training.

Instruments. Attachment patterns, symptom severity, side effects and therapeutic process measurements - working alliance, perceived empathy and session impact - will be assessed using self-report questionnaires. PS will be measured by recordings of the electrodermal activity (EDA) measured by skin conductance signals, using a galvanic skin response (GSR) device. Oxytocin Administration will be performed intranasally using a spray containing 24U.

Procedure. Sixty patients meeting inclusion criteria and their therapists will be recruited for the pilot study. Dyads will be randomized and double-blindly allocated to receive intra-nasal oxytocin or placebo. Dyads will be followed for two consecutive sessions, approximately at their fourth and fifth sessions. After signing informed consent forms, patients and therapists will complete therapeutic process measurements, and patients will be assessed for the severity of their symptoms and attachment patterns. Prior to the first session, patients will be administrated with either IN-OT or PLC and will wait for 30 minutes before the beginning of the session. Skin conductance synchrony will be measured during the session. At the end of the session, therapeutic process measurements will be assessed in both patients and therapists, and patients will complete a side-effect questionnaire. Prior to the second session, both patients and therapists will receive either IN-OT or PLC (each dyad will receive the same substance) and will wait for 30 minutes before the beginning of the session. Skin conductance synchrony will then be measured during the session. At the end of the session, therapeutic process measurements will be assessed in both patients and therapists alongside with a side-effect questionnaire.

The uniqueness of the proposed study is rooted in the view of the psychotherapy dyad as undetached, by focusing on the dyad and not on the patient alone. Focusing on patient-therapist synchronization lies on the understanding of the patient-therapist bond as co-dependent and co-affected. Such research could increase our understanding of PS between patient and therapist and its meaning in psychotherapy research and practice.

Read the detailed description

Oxytocin (OT) is a nine-amino acid neuropeptide, known to have a fundamental role in social communication. Studies have shown that OT is involved in the attachment system in mammals and in mother-infant bond. Furthermore, studies demonstrate that OT enhances the ability to trust and improves the positive effects of social support during stress. In romantic relationships, OT was found to increase positive communication during conflictual discourse between partners, and was also found to be associated with different affiliative processes, such as empathy, emotional regulation, pro-social behavior, and sense of belonging.

In a recent randomized, double-blind, placebo-controlled study carried out in Shalvata Mental Health Center, OT was administrated to patients suffering from severe mental health illness. The results indicated that OT has a clear beneficial effect on therapeutic outcomes. However, to our knowledge, the effect of OT administration to both patients and therapists on the therapeutic process was never tested. Several studies have examined the influence of different types of substances on caretakers. For example, Modafinil administration was found to improved cognitive performance of emergency physicians following overnight shifts. Another study tested the influence of melatonin administration to emergency physicians working nightshifts and found a modest improvement in their day sleep and night alertness. Substance administration to caregivers is therefore possible, and could, in some cases, provide further knowledge about the caregiving dynamics. Since we know the therapist's characteristics effect the therapeutic alliance and that OT is associated with the therapeutic alliance, patient-therapist bond, and therapy outcome, we are led to ask if OT administration to patients and therapists could allow for a deeper understanding of OT's effects on the therapeutic process.

Another variable found to be associated with the therapeutic process is Physiological Synchronization. Physiological Synchronization (PS) is a primarily interpersonal phenomenon which includes coordination of physiological signals between two or more interacting individuals. In other words, PS involves two individuals or more who mutually impact one another to the point of synchronizing, without necessary physical or visual contact. It has been suggested that PS originates during intra-uterine life between mother and fetus and to maintain through the entire human lifespan. Despite the rising number of studies examining PS, its physiological and psychological mechanisms are yet to be fully understood. Recently, Feldman (2020) has offered a model linking synchronized behavior, affiliative processes, and OT, arguing that these three components function in the service of a superordinate meaning system responsible for Human Resilience. However, to the best of our knowledge, the hypothesis of OT as the mediating neuro-hormone of PS is yet to be tested.

Based on literature indicating associations between OT and PS, and associations each of them has with the therapeutic process and its facilitators, in this study we wish to examine the influence of OT on PS through intranasal OT administration to patients alone and to patients and therapists together.

Research Hypotheses

  1. Patients receiving OT will demonstrate higher levels of PS during the measured session compared to patients receiving placebo.
  2. Patients receiving OT will report higher levels of perceived therapist empathy as compared to patients receiving placebo.
  3. These associations will be stronger when both patient and therapist receive OT in comparison to patient alone.
  4. Changed in PS and empathy will be associated with OT even after controlling for patient rated alliance and session impact.
  5. These findings will sustain after controlling for severity of symptoms and attachment patterns.

Importance of the study The uniqueness of the proposed study is rooted in the view of the psychotherapy dyad as undetached, by focusing on the dyad and not on the patient alone. Focusing on patient-therapist synchronization lies on the understanding of the patient-therapist bond as co-dependent and co-affected. Such research could increase our understanding of PS between patient and therapist and its meaning in psychotherapy research and practice. Furthermore, the implications of such study could facilitate the understanding of the mechanisms of change in psychotherapy in a way that could be manipulated in the future.

Method Participants Sixty patients and their therapists will be recruited for the pilot study. Patients will be recruited from the inpatient adult psychiatric wards at Shalvata Mental Health Center. Inclusion criteria is: (a) age above 18. (b) any type of psychiatric illness. (c) hospitalization in one of the inpatients wards. Patients will be excluded from the research if they (a) are going through a severe psychotic episode, or (b) if pregnant according to self-report. Therapists in this study will be comprised of psychologists, psychiatrists, and social workers, in different stages of seniority and training. Therapists will be excluded from the study if pregnant according to self-report.

Instruments Attachment and outcome measurements are assessed for statistical control, and the therapeutic process measurements - therapeutic alliance, perceived empathy and session impact - are the dependent variables.

The Hopkins Symptom Checklist. A self-report questionnaire measuring symptoms of depression and anxiety. The HSCL-11 is a brief version of the SCL-90-R and it includes 11 items assessing symptomatic distress. The HSCL-11 is highly correlated with the Global Severity Index (r = .91) and has high internal consistency. The measure will be utilized at baseline to assess baseline levels of distress.

The Experience in Close Relationship Scale (ECR). A self-report questionnaire evaluating anxious and avoidant attachment in adults. It consists of 36 items divided to two dimensions: 18 items reflecting anxious attachment, while the other 18 items reflecting avoidant attachment. Participants indicate the extent to which they agree/disagree with each item in terms their general experience of close relationships on a 7-point scale ranging from not at all (1) to very much (7). Reliability and validity of the ECR have been repeatedly demonstrated. The measure will be utilized at baseline to assess attachment patterns.

The Working Alliance Inventory - Short Revised (WAI - SR). A self-report questionnaire that aims to evaluate patient-therapist working alliance through three aspects: agreement on therapy goals, agreement on therapeutic tasks and patient-therapist positive emotional bond. The WAI-SR is a brief version of the original 36-item WAI, and an extended version of the 6-item Working Alliance Inventory (WAI-6). The WAI-SR consists of 12 items rated on a 6-point scale ranging from not at all (1) to very much (6). The questionnaire has two versions: one assessing the alliance from the patient's point of view and the other assessing it from the therapist's point of view. This measurement was translated to hebrew and has demonstrated excellent reliability, convergent validity, and predictive validity.

The Barrett-Lennard Relationship Inventory - Empathy Scale (BLRI). A self-report questionnaire that relies on Rogers' (1957) four essential components for the achievement of positive therapeutic change: empathic understanding, level of regard, unconditionality of regard and congruence. Together, these components form four sub-scales, each consists of 16 items, 64 items in total. For the porpuses of the current study, the empathy sub-scale will be utilized. The sub-scale consists of 16 items and is rated in a 6-point scale. The questionnaire has two versions: one measuring the perceived empathy of others towards me, which will be filled by the patient, and another measuring "my perceived empathy for others", which will be filled by the therapist. The measure was found highly reliable, with internal consistency of 0.91 for the entire questionnaire, and 0.83 for the empathy sub-scale.

Session Evaluation Questionnaire (SEQ). A self-report questionnaire assessing the effects of a psychotherapy session through different aspects of the patient's views and feelings regarding the session. It consists of a 7-point scale of 20 bipolar adjectives (for example - 1-"sad" ranging to 7-"happy"). The adjectives refer to two dimensions: session (for example - "the current session was…") and post-session (for example - "now I'm feeling…"). The SEQ is divided to four sub-scales of session and post-session: depth, flow, awareness and positivity. The depth sub-scale measures perceived efficacy and value of the session; the flow sub-scale measures perception of comfortability, calmness and peacefulness of the session; the awareness sub-scale measures the extent of energetic feeling post-session; the positiveness sub-scale measures the extent of positive feeling post-session. The SEQ demonstrated high internal consistency (α = .90) alongside high validity.

Side-effects questionnaire. A self-report scale aimed to assess potential side effects of IN-OT based on reports from past studies. It consists of 18 usual and unusual possible treatment side-effects. The questionnaire was constructed in order to provide indications of side-effects which might warrant additional safety considerations.

Electrodermal Activity (EDA). PS will be measured by the recordings of the electrodermal activity (EDA) signals using a galvanic skin response (GSR) device. The GSR device requires the attachment of two wireless electrodes to the subject's fingers. EDA was chosen due to recent developed analytic approaches for computing and interpretating PS processes based on EDA data. The AMIco algorithm identifies the picks and valleys in the EDA curves of the patient and therapist and tests their compatibility. The algorithm maximizes the probability of EDA correlation identification.

Oxytocin Administration. Intra-nasal OT (IN-OT) will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Control group (PLC) will be administered using the same spray, containing the same components but the OT. Dosage and administration method was determined by standard OT studies guidelines. The two substances will be prepared immediately after randomization by an external trained nurse who has no relations to the study. The nursing staff will administer the substance after proper training by the chief hospital pharmacist and principal investigator.

Procedure Sixty patients meeting inclusion criteria and their therapists will be recruited for the pilot study. Dyads will be randomized and double-blindly allocated to receive intra-nasal oxytocin or placebo. Dyads will be followed for two consecutive sessions, approximately at their fourth and fifth sessions. After signing informed consent forms, patients and therapists will complete therapeutic process measurements, and patients will be assessed for the severity of their symptoms and attachment patterns. Prior to the first session, patients will be administrated with either IN-OT or PLC and will wait for 30 minutes before the beginning of the session. Skin conductance synchrony will be measured during the session. At the end of the session, therapeutic process measurements will be assessed in both patients and therapists, and patients will complete a side-effect questionnaire. Prior to the second session, both patients and therapists will receive either IN-OT or PLC (each dyad will receive the same substance) and will wait for 30 minutes before the beginning of the session. Skin conductance synchrony will then be measured during the session. At the end of the session, therapeutic process measurements will be assessed in both patients and therapists alongside with a side-effect questionnaire.

Patient safety and study ethics Studies have shown that OT administration has very low potential side-effects. 5-6% of the subjects reported an increase in calmness and euphoria sensations, lightheadedness and a headache, while 3% of the subjects reported stimulated nostrils resulting from the spray administration and dry mouth. Importantly, previous studies gave evidence that OT does not harm the effectiveness of standard antidepressant medication. To ensure optimal safety, the side effects profile will be evaluated throughout the intervention period by the treating psychiatrist, and participation will be ceased if needed.

Ethically, participants will be well informed of the possibility to drop out from the study at any time. Additionally, patients will be informed that dropping out will not affect the treatment they are receiving, and that the information gathered from them will not be accessible to their therapists.

Statistical Strategy To provide initial assessment of IN-OT's effectivity compared to PLC, we will perform a comparison between the clinical courses of each dyad, using Jacobson and Truax (1991) approach for Reliable Clinical Change (index). Cohen's d will be used for effects sizes. Differences in effectivity will be demonstrated in Cramer's V, as indicators for effects sizes. Physiological Synchronization will be assessed using Truth and Bias models. All statistical analysis will be performed using SPSS software and R software.

Being tested
Intranasal Oxytocin
Keywords
Oxytocin, Physiological Synchronization, Psychotherapy
Medical subject headings
Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intranasal OxytocinDrug

    24IU (12IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.

Study groups in NCT05432089
Study groupRoleWhat they receive
Experimental GroupExperimentalNot described
Receives: Drug: Intranasal Oxytocin
Placebo GroupPlacebo comparatorNot described
Receives: Drug: Intranasal Oxytocin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. skin conductance synchrony

    as measured by GSR devices during sessions

    Measured: 1-2 weeks including 2 consecutive psychotherapy sessions

Secondary outcomes (3)
  1. working alliance

    as measured by The Working Alliance Inventory - Short Revised (WAI - SR; Hatcher \& Gillapsy, 2006).

    Measured: 1-2 weeks including 3 measurements: baseline, post-session 1 and post-session 2.

  2. perceived empathic understanding

    as measured by The Barrett-Lennard Relationship Inventory - Empathy Scale (BLRI; Barrett-Lennard, 1962).

    Measured: 1-2 weeks including 3 measurements: baseline, post-session 1 and post-session 2.

  3. session impact

    as measured by the Session Evaluation Questionnaire (SEQ; Stiles \& Snow, 1984).

    Measured: 1-2 weeks including 2 measurements: post-session 1 and post-session 2.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2022
  2. Study start30 Mar 2023
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion1 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05432089
Sponsor's protocol ID
0002-22-SHA
Status last verified
Jun 2024
First submitted
16 Jun 2022
Last updated
28 Jun 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Intranasal Oxytocin in people with Severe Mental Illness, run by Shalvata Mental Health Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Omer Sedoff, MA (+97297478555, omerse@clalit.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

skin conductance synchrony (time frame: 1-2 weeks including 2 consecutive psychotherapy sessions). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in